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Abstract 
Phosphatidylinositol (PI) signalling is an essential regulator of cell motility and proliferation. A 
portion of PI metabolism and signalling takes place in the nuclear compartment of eukaryotic cells, 
where an array of kinases and phosphatases localize and modulate PI. Among these, Diacylglycerol 
Kinases (DGKs) are a class of phosphotransferases that phosphorylate diacylglycerol and induce 
the synthesis of phosphatidic acid. Nuclear DGKalpha modulates cell cycle progression, and its 
activity or expression can lead to changes in the phosphorylated status of the Retinoblastoma 
protein, thus impairing G1/S transition and, subsequently, inducing cell cycle arrest, which is often 
uncoupled with apoptosis or autophagy induction. Here we report for the first time not only that 
the DGKalpha isoform is highly expressed in the nuclei of human erythroleukemia cell line K562, 




Phosphatidylinositol (PI) is a lipid molecule characterized by a hydrophilic head group (inositol 
ring) bound to a hydrophobic tail (glycerol and two fatty acid chains) through a phosphodiester 
link. PI is involved in many signalling pathways and its metabolism regulates important cellular 
processes including cell cycle, cell differentiation, membrane trafficking and gene expression 
(Cocco et al., 2015b). An array of kinases and phosphatases capable to modulate PI, adding or 
removing phosphate groups on the inositol ring, composes the so called PI cycle, and evidences of 
PIs and enzymes localized in the nuclear compartment have been described (Blind, 2014). This 
commonly known nuclear PI metabolism usually includes Phospholipase C (PLC), a class of 
enzymes able to hydrolyze Phosphatidylinositol 4,5-biphosphate (PI(4,5)P2) to Inositol 1,4,5-
trisphosphate (Ins(1,4,5)P3) and Diacylglycerol (DAG), important second messengers involved in 
the activation of Protein Kinases C (PKCs) and phosphorylated by Diacylglycerol Kinases (DGKs) 
(Baldanzi, 2014; Follo et al., 2015; Poli et al., 2014a; Tanaka et al., 2016; Tu-Sekine et al., 2015).  
DGKs are a family of ten proteins divided into five classes according to their specific domain 
composition. All the isoforms share the same catalytic activity: the synthesis of phosphatidic acid 
(PA) through DAG phosphorylation, using ATP as the source of the phosphate (Baldanzi, 2014). 
This event regulates different cellular functions, such as cell cycle progression and cell 
differentiation (Almena et al., 2013; Goto et al., 2014; Merida et al., 2008). As a complete PI cycle 
resides in the nucleus of eukaryotic cells, evidences collected by many studies indicated that the 
DGK activity can also be found in the nuclear matrix, suggesting the involvement of DGKs in 
nuclear processes, and particularly in cell cycle progression (Divecha et al., 1993; Payrastre et al., 
1992; Raben and Tu-Sekine, 2008; Shulga et al., 2011). For instance, DGKzeta is a negative 
regulator of cell cycle progression, as its overexpression inhibits the entry into S phase of cell cycle, 
while the silencing or inhibition its enzymatic activity accelerates cell cycle (Evangelisti et al., 2007; 
Topham et al., 1998). In addition, DGKzeta regulates G1/S transition through its interaction with 
the Retinoblastoma protein (pRb) (Los et al., 2006). On the other hand, overexpression of a kinase-
dead mutant of nuclear DGKgamma negatively affects S phase progression, and also nuclear 
DGKalpha can play a putative role in cell cycle regulation (Matsubara et al., 2006).  
DGKalpha can shuttle inside and outside the nucleus of different cell types under specific stimuli 
(Matsubara et al., 2012; Wada et al., 1996), and specific factors may either stimulate or inhibit its 
enzymatic activity. For instance, both in interleukin-2 (IL-2)-stimulated lymphocytes and in 
lymphoma cells expressing the NPM-ALK oncogene, activation of DGKalpha positively affected cell 
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cycle entry and proliferation (Bacchiocchi et al., 2005; Flores et al., 1996; Flores et al., 1999). 
Conversely, in T cells, the inhibition of DGKalpha induced by the T-cell receptor (TCR) amplified the 
TCR-induced response by enhancing the DAG-mediated signalling (Baldanzi et al., 2011; Ruffo et 
al., 2016). This different regulation and biological role of DGKalpha may be due to a specific 
subcellular distribution of DGKalpha that regulates different PA-dependent pathways, as 
demonstrated in K562 cells, where the nuclear localization of DGKalpha specifically regulates cell 
cycle (Poli et al., 2013; Poli et al., 2014b).  
Here, we report that the modulation of nuclear DGKalpha in K562 cells, through gene 
manipulation and specific DGK inhibitors, is indeed involved in cell proliferation by control of pRb 
phosphorylation and in cell cycle progression through the G1/S checkpoint. 
Materials and Methods 
Antibodies and reagents 
The following antibodies and reagents were purchased from commercial sources. DGKalpha 
(Abcam, #64845); Cyclin B1 (Santa Cruz Biotechnology; #sc-245); p-pRb 780 (Sigma-Aldrich; 
#R6275) and Beta-tubulin (Sigma-Aldrich; #T7816); pRb (Cell Signalling Technology; #9309), p-pRb 
795 (Cell Signalling Technology; #9301s), p-pRb 807/811 (Cell Signalling Technology; #9308), Cyclin 
E (Cell Signalling Technology; #4129s), Cyclin D3 (Cell Signalling Technology; #2936), Caspase-9 
(Cell Signalling Technology; #9502), Caspase-3 (Cell Signalling Technology; #9662), Beclin-1 (Cell 
Signalling Technology; #3495), LC-3b (Cell Signalling Technology; #2775) and Histone 2A (H2A, Cell 
Signalling Technology; # 2718). Secondary antibodies were horseradish peroxidase (HRP)-
conjugated anti-rabbit IgG (Cell Signalling Technology; #7074,) and HRP-conjugated anti-mouse 
IgG (Cell Signalling Technology; #7076). The Phototope®-HRP Western Blot Detection System (Cell 
Signalling Technology; #7071) was also used. 
Tissue cell cultures 
3 
Human erythroleukemia K562 cells were grown in RPMI 1640 (Sigma-Aldrich) supplemented with 
10% heat-inactivated fetal bovine serum (FBS), L-glutamine and penicillin/streptomycin. Cells were 
treated with the following compounds: DGK inhibitor I (Sigma-Aldrich, #R59022) and DGK inhibitor 
II (Sigma-Aldrich, #R59949) for 24, 48 and 72 hours. 
MTT assay 
Cells were seeded at a final density of 2 x 104 cells/well in a 96-well plate. DGK inhibitor I and II 
were added for 48h at increasing concentrations. Proliferating cells cultivated in complete RPMI 
1640 with 10% FBS were used as the control, whereas wells filled with only the medium were 
considered as the background. MTT experiments were performed following the manufacturer’s 
instructions (Life Technologies). Data were analyzed reading the absorbance at 570 nm. All results 
were compared with the control samples after subtraction of the values given by the background. 
Results were statistically analyzed by GraphPad Prism software (v. 6.0) and Student’s t-test was 
used to compare continuous values. 
Cell Counting 
To determine the rate of cell growth, cells were seeded at a cell density of 2.5 x 104 cells/ml in 12-
well plates and, then, treated with DGK inhibitor I and DGK inhibitor II (Sigma-Aldrich). In the 
experiments of gene manipulation, cells were transfected to overexpress/silence DGKalpha, or 
with an empty vector/scrambled siRNA as control, and 2 hours later seeded in complete RPMI 
1640 10% FBS at the same cell density (2.5 x 104 cells/ml in 12-well plates). Cell growth was 
determined by direct counting of cells harvested at 24, 48 and 72 hours after seeding. Viable cells 
were counted by a hemocytometer using 0.2% Trypan Blue. Results were statistically analyzed by 
GraphPad Prism software (v. 6.0) and Student’s t-test was used to compare continuous values. 
Cell cycle synchronization 
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Growing cells were collected and synchronized: (1) G1/S cells: proliferating cells were cultured in 
complete RPMI 1640 with FBS 10%; (2) G2/M blocked cells: growing cells were treated with 
Nocodazole (Sigma-Aldrich) at a final concentration of 20 ng/ml for 16 hours; (3) G0/G1 cells: 
growing cells were synchronized at G2/M by 20 ng/ml Nocodazole treatment for 16 hours before 
being released for 3 hours in complete RPMI 1640 10% FBS. 
Cell transfection 
Cells were seeded at a cell density of 5 × 105 cells/ml in 6-well plates, then cells were transfected 
with full-length DNA vectors for human DGKalpha cloned into YFP-pDEST 6.2, using an empty 
pcDNA/2.1 plasmid (Invitrogen) as a control. Conversely, the expression of DGKalpha was silenced 
by a specific siRNA (Applied Biosystems) at a final concentration of 50 nM, using the 
electroporation assay kit (Tema Ricerca, program T-16) as indicated by the manufacturers’ 
instructions, while a mix of Silencer Select Negative Control #1 and #2 siRNAs (Applied Biosystems) 
was used as a negative control. 24 hours after transfection (overexpression/silencing), K562 cells 
were treated with both DGK inhibitor I and DGK inhibitor II at a final concentration of 20 μM for 24 
hours. 
Flow cytometric analysis of cell cycle 
For cell cycle analysis, cells were cultivated in RPMI medium with the addition of DGK inhibitor I 
and DGK inhibitor II (Sigma-Aldrich), and the analysis was performed as reported elsewhere 
(Chiarini et al., 2010). At least 10,000 events/sample were acquired. Results were statistically 
analyzed by GraphPad Prism software (v. 6.0) and Student’s t-test was used to compare 
continuous values. 
Annexin V/PI assay 
Annexin V/PI analyses were performed as indicated by the manufacturer’s instructions (Life 
Technologies), as previously reported (Lonetti et al., 2014). Cells were treated with DGK inhibitor I 
and DGK inhibitor II at a final concentration of 20 μM for 48 hours. Then, the assay was performed 
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acquiring at least 5000 events per sample. Results were statistically analyzed by GraphPad Prism 
software (v. 6.0) and Student’s t-test was used to compare continuous values. 
Analysis of DGKalpha Gene Expression 
Total RNA was extracted and retro-transcribed as previously reported (Cocco et al., 2015a). The 
expression of DGKalpha gene was assessed using a standard TaqMan Real-Time PCR method 
(Applied Biosystems), with the 18s TaqMan probe as the endogenous control (Applied 
Biosystems). Results were statistically analyzed by GraphPad Prism software (v. 6.0) and Student’s 
t-test was used to compare continuous values.
Analysis of Protein Expression 
Protein amount was assessed by Western Blot analyses, and nuclear and cytoplasmic fractionation 
was performed as already reported (Blalock et al., 2011). Beta-tubulin was used as a control of 
equal protein loading. Purity of nuclear and cytoplasmic fractionations were controlled using Beta-
tubulin (cytoplasmic marker) and H2A (nuclear marker) antibodies.  
Results 
Nuclear localization of DGKalpha isoform in K562 cells 
As Figure 1a shows, K562 cells were induced to a specific and complete synchronization at the 
three different checkpoints. The levels of DGKalpha were then investigated in both cytoplasmic 
and nuclear fractions of these synchronized cells. As Figure 1b shows, DGKalpha appeared to be 
mainly localized inside the nucleus of K562 cells and, even if slightly, showed a peak at the G2/M 
checkpoint. On the contrary, DGKalpha was barely expressed in the cytoplasmic fraction of this cell 
line (Figure 1b).  
Inhibition of DGK signalling impairs K562 cell proliferation 
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Both DGK inhibitor I and II, also called R59022 and R59949 respectively, inhibit DGKalpha activity 
with a IC50 of about 20 µM (Sato et al., 2013). In a dose-response MTT assay, both DGK inhibitors 
significantly downregulated cell proliferation at concentrations higher than 10 μM and an ED50 of 
20 μM, whereas higher concentrations drove to a very strong decrease of the MTT signal, 
suggesting a toxic effect (Figure 2a). Cell growth analyses completely matched the MTT data, 
showing no changes in cell proliferation by treatment with DGK inhibitor I or II at final 
concentrations up to 10 μM, whereas doses equal or higher than 20 μM appeared to slow down 
proliferation (Figure 2b).  
K562 cells treated with DGK inhibitors I and II show accumulation in the G0/G1 phase of cell 
cycle and a reduced phosphorylation of pRb 
When compared with proliferating cells, the treatment with both DGK inhibitors induced a 
relevant accumulation of K562 cells at the G0/G1 phase of cell cycle and a consistent reduction of 
cells in both S and G2/M phases (Figure 2c).  
Moreover, also the expression of some proteins regulating cell cycle machinery was screened by 
Western blot (Figure 2d). Interestingly, DGK inhibitor I and DGK inhibitor II led to important 
decrease of the phosphorylation status of pRb, while the levels of the total protein did not change. 
On the other hand, Cyclin E seemed not affected, whereas a slight increase of Cyclin D3 and a 
strong downregulation of Cyclin B1 were found (Figure 2d).  
Impaired cell cycle by inhibition of DGK signalling is not linked to upregulation of apoptosis or 
autophagy 
In order to further investigate the role of DGKalpha in cell cycle regulation, we treated K562 cells 
with the two DGK inhibitors for 48 hours and, then, we collected and stained the cells with 
Annexin V/PI in order to quantify the apoptotic (Annexin V+) or necrotic (PI+) ones. Surprisingly, 
48 hours of treatment with 20μM of either DGK inhibitor I or II led to cell accumulation at G0/G1, 
without affecting the percentage of apoptotic or necrotic cells (Figure 3a), and the expression of 
both full-length and cleaved Caspases 9 and 3 (Figure 3b). Finally, no changes in the levels of 
Beclin-1 and LC3b, essential regulators of authophagy, were observed (Figure 4).  
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Modulation of nuclear DGKalpha affects cell cycle progression through the G1/S transition 
In order to evaluate the specific role of DGKalpha isoform, we knocked down its expression by 
transfecting K562 with a specific DGKalpha siRNA. As shown in Figure 5a, qPCR and Western blot 
analyses confirmed the downregulation of DGKalpha mRNA and protein in K562 cells. In particular, 
we found that upon DGKalpha knock down, cell proliferation was significantly reduced if 
compared with the scrambled controls (Figure 5b). Next, cell cycle profiling was investigated. 
Strikingly, 48h after the transfection, DGKalpha knocked down cells showed an important 
accumulation at the G0/G1 phase (Figure 5c).  
On the other hand, the overexpression of DGKalpha (DGKalpha OV) led to a relevant increase of 
the protein levels in K562 cells (Figure 5d) and cell proliferation assays showed a slight increase in 
overexpressing cells (Figure 5e). In addition, 48 hours after the transfection, cell cycle analyses 
indicated a significant increase of cells overexpressing DGKalpha in the S phase, as compared with 
control cells (Figure 5f). Subsequently, we overexpressed DGKalpha and, 24 hours later, we 
treated K562 cells with DGK inhibitor I or DGK inhibitor II for further 24 hours. Cell cycle analyses 
indicated that the effects of inhibition of cell cycle progression by both DGK inhibitor I and II were 
partially limited by overexpression of DGKalpha. Indeed, as shown in Figure 6, DGKalpha 
upregulation led the cells to partially overcome the G0/G1 block, leading to a significant increase 
in the percentage of cells in S phase.  
Discussion 
Many reports indicate that DGKs are localized also in the nucleus, where they may phosphorylate 
nuclear DAG to generate PA, making these enzymes as part of nuclear PI metabolism (Payrastre et 
al., 1992; Raben and Tu-Sekine, 2008; Vann et al., 1997). On the other hand, oscillations of the 
nuclear pool of PIs during cell proliferation, including PA synthesis, have been observed as able to 
modulate cell cycle progression (Bulley et al., 2015; Giudici et al., 2016; Irvine, 2003; Shulga et al., 
2011). In this study we focused on a specific DGK isoform, DGKalpha, whose localization in the 
nucleus was detectable in specific cell types (Raben and Tu-Sekine, 2008). Despite some 
preliminary evidences suggested that nuclear DGKalpha is involved in nuclear PI metabolism and 
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in cell proliferation, its role still remains to be fully elucidated (Bacchiocchi et al., 2005; Baldanzi et 
al., 2011; Flores et al., 1996; Flores et al., 1999). We recently described that a robust nuclear DAG 
increase, due to nuclear PLCbeta1 activity, drives human K562 erythroleukemia cell line through 
the G2/M checkpoint of cell cycle (Poli et al., 2014b). Moreover, D'Santos et al. showed that, in 
K561 cells, the down- and up-regulation of nuclear DAG and PA contribute to overpass mitosis and 
induce cells to enter the G0/G1 phase, thus suggesting a key role for DGK enzymes in this process 
(D'Santos et al., 1999).  
Stemming from these data, here we intended to elucidate the contribution of DGKalpha, which is 
highly expressed in the nucleus of K562 cells, in nuclear PI modulation, by carrying out DAG 
phosphorylation to PA, and we were also interested in investigating the putative role of DGKalpha 
in driving cells through the G0/G1 checkpoint and enter into the S phase during cell cycle 
progression and cell proliferation.  
Our data support the notion that DGKalpha is part of a well-defined nuclear PI metabolism able to 
affect cell cycle and cell proliferation of K562 human erythroleukemia cell line. Indeed, the 
participation of DGK activity in nuclear PI metabolism is known and several DGK isoforms, such as 
DGKtheta and DGKzeta, have been observed in the nucleus (Evangelisti et al., 2007; Merida et al., 
2008; Shulga et al., 2011). While DGKalpha is known to shuttle between the nucleus and 
cytoplasm/plasma membrane (Baldanzi et al., 2011; Matsubara et al., 2012), here we report for 
the first time that this specific isoform is strongly localized into the nucleus of K562 
erythroleukemia cells. Indeed, synchronization experiments at different cell cycle checkpoints 
showed an important expression of DGKalpha in the nuclear fraction of this cell model, slightly 
peaking at G2/M. This suggested that DGKalpha might have a function in nuclear signalling. In 
particular, we observed that the inhibition of DGK signalling by treatment with DGK inhibitor I and 
DGK inhibitor II can down-modulate K562 cell proliferation, specifically affecting G1/S transition. 
Cells treated with both these compounds were indeed characterized by an important block at the 
G0/G1 checkpoint and a parallel reduction of the S and G2/M phases. This impaired cell cycle 
phenotype was due to a strong decrease of the levels of phosphorylation of pRB, which is an 
essential process for the detachment of pRb from E2F and, in turn, for cell cycle entry into S phase. 
Moreover, we also observed a slight increase of Cyclin D3 and an important reduction of Cyclin B1 
expression, linked with the peculiar G1 accumulation and the diminished G2/M phase in the cells. 
Interestingly, the G0/G1 block obtained by DGK inhibition did not lead to induction of apoptosis or 
autophagy.  
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Furthermore, as we have previously documented the relevance of nuclear PI cycle for cell 
proliferation in K562 cells (Poli et al., 2013; Poli et al., 2014b), given that DGKalpha has a strong 
nuclear localization in this cell model, and considering that both DGK inhibitor I and II can 
specifically inhibit K562 cell proliferation, we decided to elucidate if DGKalpha could be involved in 
nuclear signalling and cell cycle regulation. Interestingly, when DGKalpha was silenced in K562 
cells, we obtained a cell cycle profile which was a phenocopy of the one obtained by treating the 
cells with DGK inhibitors I and II, with an important accumulation at G0/G1. Conversely, when we 
overexpressed DGKalpha, we observed a slight increase in cell proliferation, with a major 
accumulation in the S phase. Finally, upon overexpression of DGKalpha, the effects of both DGK 
inhibitor I and DGK inhibitor II were sharply reduced, indicating that both inhibitors were titrated 
out by DGKa overexpression, and suggesting that this specific isoform was the inhibitor target 
relevant for the modulation of cell cycle. Altogether, these data demonstrate that DGKalpha 
modulates K562 cell cycle, putatively by participating to the nuclear PI cycle. The molecular 
mechanism by which nuclear DGKalpha controls pRb phosphorylation and cell cycle are currently 
unknown, but they may be of general interest in the hematopoietic system, as similar effects were 
reported in lymphocytes treated with DGK inhibitors (Flores et al., 1999). The evidences reported 
in this study may therefore contribute to consider DGKalpha as part of the important machinery 
regulating PI metabolism in the nuclear compartment of K562 cells and, consequently, 
fundamental processes affecting cell cycle and cell proliferation. 
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Figures 
Figure 1. DGKalpha is highly located located into the nuclear compartment of K562 cells. a) Cell 
cycle analyses showing K562 cell synchronization at the G1/S, G2/M and G0/G1 phase of the cell 
cycle. b) Nuclei and cytoplasms of synchronized K562 cells were separated. Immunoblot assay 
indicated DGKalpha as highly present in the nuclear compartment of K562 cells, slightly peaking at 
the G2/M phase. 
Figure 2. DGK inhibition drives cells to accumulate into G0/G1 and to changes in Cyclin and p-
pRb levels. a) K562 cell proliferation was quantified after 48h treatment with DGK inhibitor I (DI) 
and DGK inhibitor II (DII) at different final concentrations (DI 5-10-20-30-50 μM / DII 5-10-20-30-50 
μM). Cell growth was significantly down-regulated starting from 20 μM to 50μM if compared to 
control cells (Ctrl). Data were collected by three independent analyses ± SD. ***p<0.05 vs. Ctrl. b) 
Cell counting experiments confirmed that cell proliferation was slowed down by DGK inhibition (DI 
5-10-20-30 μM / DII 5-10-20-30 μM / Control). Data were collected by three independent analyses
± SD. ***p<0.05 vs. Ctrl. c) Cell cycle analysis showed accumulation at the G0/G1 phase after 
treatment with DGK inhibitors I and II at 20 μM for 48h (DGK inh I 20 μM 48h/ DGK inh II 20 μM 
48h). Data were collected by three independent analyses ± SD. **p<0.05 vs. Ctrl. DGK inhibition 
led to minor G1/S transition if compared with control cells (Ctrl 48h). d) Western blot analyses of 
proteins involved in cell cycle regulation indicated that DGK inhibition (DGK inhibitor I 48h / DGK 
inhibitor II 48h) induced a slight increase of Cyclin D3, a minor expression of Cyclin B1 and a 
diminished phosphorylation of pRb.  
Figure 3. DGK signaling inhibition did not lead to changes in the expression of autophagy 
markers. K562 cells were treated with DGK inhibitor I and DGK inhibitor II for 48 hours (DGK 
inhibitor I 48h - DGK inhibitor II 48h) and the expression of Beclin 1 and LC-3b, markers of 
autophagy, was investigated. No changes in their levels were detected as compared with control 
cells (Control). 
Figure 4. Cell cycle arrest at G0/G1 phase is not followed by apoptosis. a) Cells were treated for 
48 hours with DGK inhibitor I and II (DGK inhibitor I 48h / DGK inhibitor II 48h and Annexin-V assay 
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was performed. No changes in the percentage of apoptotic cells were detected comparing DGK 
inhibitors treatments with normal proliferating control cells (Control 48h). b) Protein expression of 
caspase 3 and caspase 9 (both total and cleaved forms) showed no differences among the 
different samples (DGK inhibitor I 48h/ DGK inhibitor II 48h/ Control 48h). 
Figure 5. Nuclear DGKalpha modulation is involved in K562 proliferation and cell cycle 
regulation. a) Knock-down of DGKalpha was obtained using specific siRNA (DGKalpha KD), whereas 
control cells were transfected with a mix of scrambled siRNAs (Scrambled). Immunoblot and Real-
Time PCR analyses confirmed both the gene and protein silencing. b) Cells were transfected with 
DGKalpha siRNA (DGKalpha KD) and with Scrambled siRNAs (Scrambled), seeded at a final cell 
density of 2.5 x 104 cells/ml and counted after 24-48-72 hours. Slow-down of cell proliferation was 
detected only in DGKalpha KD cells. c) 48 hours after transfection, cells with DGKalpha knock-
down (DGKalpha KD 48h) showed an accumulation at the G0/G1 phase, if compared with the 
control (Scrambled 48h). d) Overexpression of DGKalpha was obtained using a specific vector 
encoding a wild type protein (DGKalpha OV). As control, cells were transfected with an empty 
vector (Empty). Immunoblot and Real-Time PCR analyses confirmed the overexpression. e) Cells 
were transfected with DGKalpha (DGKalpha OV) and with an empty vector (Empty Vector), then 
seeded at a final cell density of 2.5 x 104 cells/ml and counted after 24-48-72 hours. A slight 
increase of cell proliferation was detected in DGKalpha OV cells. f) 48 hours after transfection, cell 
cycle profile of cells overexpressing DGKalpha (DGKalpha OV) showed a higher percentage of cells 
progressing into S phase, if compared with the control (Empty). Data were collected by three 
independent analyses ± SD. *p < 0.05. 
Figure 6. Overexpression of DGKalpha partially restores the normal cell cycle phenotype of cells 
treated with DGK inhibitor I and DGK inhibitor II. K562 cells were transfected with a DGKalpha 
vector and with an empty vector as control. 24 hours after the procedure, cells were treated with 
both DGK inhibitor I and II for other 24 hours and cell cycle profile was analyzed. Cells with 
DGKalpha overexpression (DGKalpha OV + DGK inh I / DGKalpha OV + DGK inh II) showed a 
diminished G0/G1 accumulation after DGK inhibition as compared with cells transfected with the 
empty vector (Empty + DGK inh I / Empty + DGK inh II), indicating that DGKalpha was able to 
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attenuate the effects of DGK inhibitors I and II. Data were collected by three independent analyses 
and cell cycle experiments were analyzed by Student’s t-test. *p < 0.05. 
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